Researchers at the Duke University Medical School have announced a potential breakthrough in cancer treatment, which may be more accurate and less destructive to healthy cells than existing methods of therapy. Dr. Jose's leadership research is focused on the use of dimer IgA (Diga) antibodies to influence molecules that contribute to the development of a tumor within cancer cells.
Diga antibodies are able to specifically affect mutations associated with PIGR protein, present in most epithelial cancer cells. One of the aggressive mutations, Kras G12D, can be stopped by Diga antibodies in the process of transcitosis, which has proven to be more effective than modern treatments.
Testing on mice with lung and colon cancer showed a significant decrease in tumor growth when using this antibody. The study also revealed promising results on another mutation, IDH1 R132H.
The peculiarity of this study is the ability of Diga antibodies to penetrate the cells, which was previously a difficult task. This approach allows you to more accurately affect tumor cells, expeling molecules that contribute to the development of the tumor and prevent its growth.
Dr. Koneho-Harzia argues that antibody can be used to treat various forms of aggressive epithelial cancers, including ovarian cancer, colon and lungs.
These results are part of the developed immunotherapy industry aimed at using the immune system to combat cancer. The new method shows considerable potential in cancer treatment, which can be an important step in combating this ailment.
The research was completed at the Center for the H. Moffitt H. Moffitt Research Center and the antibodies for future clinical trials are currently being completed.
